Peer-reviewed veterinary case report
Protein profiling and assessment of amyloid beta levels in plasma in canine refractory epilepsy.
- Journal:
- Frontiers in veterinary science
- Year:
- 2023
- Authors:
- Phochantachinda, Sataporn et al.
- Affiliation:
- Department of Clinical Sciences and Public Health
- Species:
- dog
Plain-English summary
This study looked at the levels of a protein called amyloid beta in the blood of dogs with a type of epilepsy that doesn't respond well to treatment, compared to healthy dogs. They found that dogs with epilepsy had much higher levels of amyloid beta in their blood than healthy dogs. The researchers also identified changes in 155 different proteins, with some proteins being less active and others more active in dogs with epilepsy, suggesting that inflammation in the brain might be involved in their seizures. The findings indicate that certain proteins could help in diagnosing epilepsy in dogs and understanding how the disease affects them. Overall, the study suggests that these proteins might be important in managing canine epilepsy, but more research is needed to fully understand their roles.
Abstract
INTRODUCTION: The relationship between epilepsy and cognitive dysfunction has been investigated in canines, and memory impairment was prevalent in dogs with epilepsy. Additionally, canines with epilepsy have greater amyloid-β (Aβ) accumulation and neuronal degeneration than healthy controls. The present study investigated plasma Aβlevels and performed proteomic profiling in dogs with refractory epilepsy and healthy dogs. METHODS: In total, eight dogs, including four healthy dogs and four dogs with epilepsy, were included in the study. Blood samples were collected to analyze Aβlevels and perform proteomic profiling. Changes in the plasma proteomic profiles of dogs were determined by nano liquid chromatography tandem mass spectrometry. RESULTS AND DISCUSSION: The plasma Aβlevel was significantly higher in dogs with epilepsy (99 pg/mL) than in healthy dogs (5.9 pg/mL). In total, 155 proteins were identified, and of these, the expression of 40 proteins was altered in epilepsy. Among these proteins, which are linked to neurodegenerative diseases, 10 (25%) were downregulated in dogs with epilepsy, whereas 12 (30%) were upregulated. The expression of the acute phase proteins haptoglobin and α2-macroglobulin significantly differed between the groups. Complement factor H and ceruloplasmin were only detected in epilepsy dogs, suggesting that neuroinflammation plays a role in epileptic seizures. Gelsolin, which is involved in cellular processes and cytoskeletal organization, was only detected in healthy dogs. Gene Ontology annotation revealed that epilepsy can potentially interfere with biological processes, including cellular processes, localization, and responses to stimuli. Seizures compromised key molecular functions, including catalytic activity, molecular function regulation, and binding. Defense/immunity proteins were most significantly modified during the development of epilepsy. In Kyoto Encyclopedia of Genes and Genomes pathway analysis, complement and coagulation cascades were the most relevant signaling pathways affected by seizures. The findings suggested that haptoglobin, ceruloplasmin, α2-macroglobulin, complement factor H, and gelsolin play roles in canine epilepsy and Aβ levels based on proteomic profiling. These proteins could represent diagnostic biomarkers that, after clinical validation, could be used in veterinary practice as well as proteins relevant to disease response pathways. To determine the precise mechanisms underlying these relationships and their implications in canine epilepsy, additional research is required.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/38192726/